(ECNS) -- China's Sinopharm unveiled four types of COVID-19 vaccines, three diagnostic reagents and two specific drugs at the ongoing 2021 China International Fair for Trade in Services (CIFTIS).
Among them, second-generation vaccines against variants and drugs for COVID-19 attracted much attention.
The four types of vaccines are based on three technical routes: inactivated, recombinant protein and mRNA technology, according to Chen Kun, Secretary of the Commission for Discipline Inspection at China National Biotec Group, a unit of Sinopharm.
Its second-generation broad-spectrum recombinant protein vaccine is tailored against variants.
Two inactivated vaccines developed by the company's subsidiary Beijing Institute of Biological Products and Wuhan Institute of Biological Products are upgraded versions of an inactivated vaccine that's already on the market, Chen said.
They can effectively neutralize mutant strains.
The company-owned mRNA vaccine is currently in the process of preclinical research and a production workshop is under construction for it.
Sinopharm also showcased two drugs for COVID-19, specific immunoglobulin and monoclonal antibodies.
The specific immunoglobulin medication, which was approved for clinical trials on Aug. 30, is the world's first drug that uses plasma from healthy people fully immunized with inactivated vaccines.
In addition, the monoclonal antibody medication capable of effectively neutralizing variants is currently in preclinical research.